OncoMatch/Clinical Trials/NCT06448754
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Is NCT06448754 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Volrustomig · Carboplatin · Pemetrexed · Ramucirumab · Paclitaxel — Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Absence of sensitizing epidermal growth factor receptor (EGFR) mutations
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease allowed if progression > 12 months from end of last therapy
Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
Cannot have received: systemic therapy
Exception: prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease allowed if progression > 12 months from end of last therapy
Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Adequate organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Los Angeles, California
- Research Site · Grand Junction, Colorado
- Research Site · Wheat Ridge, Colorado
- Research Site · Baltimore, Maryland
- Research Site · Detroit, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify